Treatment Intensification Across Disease Presentations in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

In this segment, Dr. Charles J. Ryan asks Dr. Murilo De Almeida Luz to discuss how treatment intensification strategies may differ across various clinical presentations of metastatic castration sensitive prostate cancer (mCSPC). Dr. Luz explains that factors such as disease volume, timing of metastasis, and prior treatment history can influence therapeutic decision making. He notes that patients with de novo metastatic disease or high volume disease often have more aggressive clinical courses and may benefit from earlier intensification strategies. At the same time, the discussion highlights that treatment approaches must remain individualized, particularly for patients with low volume or recurrent metastatic disease following prior local therapy. Dr. Luz emphasizes the importance of evaluating disease burden, patient comorbidities, and overall treatment goals when selecting therapy. The segment underscores how clinicians integrate clinical trial evidence with real world patient characteristics to tailor treatment intensification strategies for individuals with metastatic castration sensitive prostate cancer.